Fig. 6.

HspB2 inhibits the anti-tumor effects of TRAIL in vivo. Female athymic nude mice with established orthotopic MDA-MB-231 mammary tumors expressing HspB2 or vector were treated with PBS (vehicle) or 5 mg/kg/day TRAIL by intraperitoneal injection (four groups of five mice each) for 5 weeks. Tumor volume was measured weekly. The data represent the mean ± SEM of tumors from five mice/group. (***P < 0.001 versus mammary tumors stably expressing vector treated with TRAIL)